Publication digest

View our publication digests to learn key findings on the use of CDK4/6 inhibitors for treatment of HR+/HER2−, node-positive, high-risk early breast cancer.

• Review data comparing clinical outcomes for various CDK4/6 inhibitors
• Learn the long-term benefits of adjuvant abemaciclib combined with endocrine therapy
• Consider the safety and tolerability profile of this combination therapy for breast cancer